Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Create more data on roflumilast efficacy, says NICE

By News team

Clinical trials need to be set up to establish how effective roflumilast is before the drug can be recommended for NHS use, the National Institute for Health and Clinical Excellence has said.

In final guidance published today (25 January 2012), NICE’s independent technology appraisal committee concluded that the NHS would benefit from having robust trial data on the clinical and cost effectiveness of roflumilast (Daxas; Merck, Sharp & Dohme).

In other guidance, NICE recommended apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for use on the NHS in England and Wales.

It also endorsed the use of rituximab (MabThera, Roche), in combination with a range of chemotherapy regimens, for the first-line treatment of advanced follicular lymphoma. The drug is recommended for use in combination with: cyclophosphamide, vincristine and prednisolone; mitoxantrone, chlorambucil and prednisolone; cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon alfa; or chlorambucil.

Evidence shows that the addition of rituximab helps patients to live longer and improves quality of life, compared with chemotherapy alone, NICE says.

Citation: The Pharmaceutical Journal URI: 11093677

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Daxas pack shot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.